Veracyte Inc reports results for the quarter ended March 31 - Earnings Summary

Veracyte

07/05/2025 22:42

Veracyte Inc VCYT.OQ reported quarterly adjusted earnings of 9 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of thirteen analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from -4 cents to 22 cents per share.

Revenue rose 18.2% to $114.47 million from a year ago; analysts expected $111.11 million.

Veracyte Inc's reported EPS for the quarter was 9 cents​.

The company reported quarterly net income of $7.05 million.

Veracyte Inc shares had risen by 3.1% this quarter and lost 22.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 43.1% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Veracyte Inc is $45.00

This summary was machine generated from LSEG data May 7 at 09:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
0.05
0.09
Beat
Dec. 31 2024
0.11
0.06
Missed
Sep. 30 2024
0.03
0.19
Beat
Jun. 30 2024
-0.02
0.07
Beat